Silymarin, being the flavonoid complex isolated from Silybum marianum fruits is widely used and has new prospects to be used in medicine. Silybin (also known as silibinin) is main component of silymarin with attributed therapeutically properties. Silymarin behave as weak acid, can be considered as a Class II drug and has slow dissolution kinetics at pH 7.4 and low bioavailability (1). The inhibition of gut wall efflux with additional formulation components, the bypassing the gut wall efflux by lymphatic transport and the increasing intestinal flux by increasing of drug concentration in the place of absorption are well-known strategies for the improvement of bioavailability. The main objective of this study was to justify the chosen formulation strategy and to investigate the drug release of silymarin as function of carrier type (Avicel® PH-102 vs. Syloid® XDP 3150) and surface-active substance (Tween® 80) concentration.
|Publication status||Published - 11 May 2021|
|Event||12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology - Vienna, Austria|
Duration: 11 May 2021 → 14 May 2021
|Conference||12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology|
|Period||11/05/2021 → 14/05/2021|